These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 21626233)

  • 1. Old issues and new perspectives on prostate cancer hormonal therapy: the molecular substratum.
    Reis LO
    Med Oncol; 2012 Sep; 29(3):1948-55. PubMed ID: 21626233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
    Sharifi N
    Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN; Schröder FH
    BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond T and DHT - novel steroid derivatives capable of wild type androgen receptor activation.
    Mostaghel EA
    Int J Biol Sci; 2014; 10(6):602-13. PubMed ID: 24948873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New hormonal therapies for castration-resistant prostate cancer.
    Mostaghel EA; Plymate S
    Endocrinol Metab Clin North Am; 2011 Sep; 40(3):625-42, x. PubMed ID: 21889725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormonal therapy for prostate cancer: toward further unraveling of androgen receptor function.
    Sharifi N
    Anticancer Agents Med Chem; 2009 Dec; 9(10):1046-51. PubMed ID: 19719456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.
    Li Y; Chan SC; Brand LJ; Hwang TH; Silverstein KA; Dehm SM
    Cancer Res; 2013 Jan; 73(2):483-9. PubMed ID: 23117885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.
    Cai C; Chen S; Ng P; Bubley GJ; Nelson PS; Mostaghel EA; Marck B; Matsumoto AM; Simon NI; Wang H; Chen S; Balk SP
    Cancer Res; 2011 Oct; 71(20):6503-13. PubMed ID: 21868758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer.
    Mitsiades N
    Cancer Res; 2013 Aug; 73(15):4599-605. PubMed ID: 23887973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer.
    Chatterjee B
    Mol Cell Biochem; 2003 Nov; 253(1-2):89-101. PubMed ID: 14619959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones.
    Taplin ME; Manola J; Oh WK; Kantoff PW; Bubley GJ; Smith M; Barb D; Mantzoros C; Gelmann EP; Balk SP
    BJU Int; 2008 May; 101(9):1084-9. PubMed ID: 18399827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen Signaling in Prostate Cancer.
    Dai C; Heemers H; Sharifi N
    Cold Spring Harb Perspect Med; 2017 Sep; 7(9):. PubMed ID: 28389515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular pathogenesis and progression of prostate cancer.
    Schrecengost R; Knudsen KE
    Semin Oncol; 2013 Jun; 40(3):244-58. PubMed ID: 23806491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular biology of castration-resistant prostate cancer: basis for the novel therapeutic targets.
    Mellado B; Marin Aguilera M; Pereira MV
    Arch Esp Urol; 2013 Jun; 66(5):453-62. PubMed ID: 23793763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
    Hu R; Lu C; Mostaghel EA; Yegnasubramanian S; Gurel M; Tannahill C; Edwards J; Isaacs WB; Nelson PS; Bluemn E; Plymate SR; Luo J
    Cancer Res; 2012 Jul; 72(14):3457-62. PubMed ID: 22710436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The androgen/androgen receptor axis in prostate cancer.
    Bluemn EG; Nelson PS
    Curr Opin Oncol; 2012 May; 24(3):251-7. PubMed ID: 22327838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular biology of androgen-independent prostate cancer: the role of the androgen receptor pathway.
    Mellado B; Codony J; Ribal MJ; Visa L; Gascón P
    Clin Transl Oncol; 2009 Jan; 11(1):5-10. PubMed ID: 19155198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Manipulation of androgens and alterations in the androgen receptor axis in prostate cancer.
    Nguyen MM; Wang Z
    Minerva Urol Nefrol; 2008 Mar; 60(1):15-29. PubMed ID: 18427432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intratumoral conversion of adrenal androgen precursors drives androgen receptor-activated cell growth in prostate cancer more potently than de novo steroidogenesis.
    Kumagai J; Hofland J; Erkens-Schulze S; Dits NF; Steenbergen J; Jenster G; Homma Y; de Jong FH; van Weerden WM
    Prostate; 2013 Nov; 73(15):1636-50. PubMed ID: 23996639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.